Adaptive Biotechnologies (ADPT) Total Debt (2022 - 2026)

Adaptive Biotechnologies (ADPT) has 5 years of Total Debt data on file, last reported at $130.6 million in Q1 2026.

• Quarterly Total Debt fell 2.25% year-over-year to $130.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.6 million (down 2.25% YoY) and the FY2025 annual result came in at $131.2 million, down 1.55% from the prior year.
• Total Debt steadied at $130.6 million in Q1 2026 per ADPT's latest filing, from $131.2 million in the prior quarter.
• The five-year high for Total Debt was $133.6 million in Q2 2025, with the low at $125.4 million in Q4 2022.
• Average Total Debt over 5 years is $131.4 million, with a median of $131.7 million recorded in 2024.
• Year-over-year, Total Debt advanced 4.23% in 2023 and decreased 2.25% in 2026.
• Adaptive Biotechnologies' Total Debt stood at $125.4 million in 2022, then rose by 4.23% to $130.7 million in 2023, then advanced by 2.0% to $133.3 million in 2024, then declined by 1.55% to $131.2 million in 2025, then slipped by 0.5% to $130.6 million in 2026.
• Business Quant data shows ADPT's Total Debt at $130.6 million in Q1 2026, $131.2 million in Q4 2025, and $131.8 million in Q3 2025.